New-prescription Alert for Deep Vein Thrombosis

N/A
Recruiting
Led By Geoffrey Barnes, MD
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must not have
Timeline
Screening 3 weeks
Treatment Varies
Follow Upmonth 0, up to 18 months
Awards & highlights
No Placebo-Only Group

Study Summary

This trial will test whether getting alerts about high-risk prescriptions from pharmacists, instead of doctors, will lead to more changes in prescriptions.

Eligible Conditions
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism
  • Atrial Fibrillation

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 0, up to 18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and month 0, up to 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The number (proportion) of notifications (in the existing-prescription notification conditions) that are addressed within 7 days.
Secondary outcome measures
Change in effect size for the existing-prescription notification over time
Change in effect size for the initial alert over time
The number (proportion) of alerts (in the newly prescribed DOAC alert conditions) that are addressed within 7 days.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: New-prescription Alert/ Existing-prescription notification to pharmacistExperimental Treatment2 Interventions
Group II: New-prescription Alert w/ referral option/ Existing-prescription notification to prescriberExperimental Treatment2 Interventions
Group III: New-prescription Alert w/ referral option/ Existing-prescription notification to pharmacistExperimental Treatment2 Interventions
Group IV: New-prescription Alert / Existing-prescription notification to prescriberExperimental Treatment2 Interventions

Find a site

Who is running the clinical trial?

University of MichiganLead Sponsor
1,718 Previous Clinical Trials
6,562,782 Total Patients Enrolled
2 Trials studying Deep Vein Thrombosis
133 Patients Enrolled for Deep Vein Thrombosis
Agency for Healthcare Research and Quality (AHRQ)FED
386 Previous Clinical Trials
7,053,072 Total Patients Enrolled
3 Trials studying Deep Vein Thrombosis
1,078 Patients Enrolled for Deep Vein Thrombosis
Geoffrey Barnes, MDPrincipal Investigator
University of Michigan

Media Library

New-prescription Alert Clinical Trial Eligibility Overview. Trial Name: NCT05351749 — N/A
Deep Vein Thrombosis Research Study Groups: New-prescription Alert / Existing-prescription notification to prescriber, New-prescription Alert w/ referral option/ Existing-prescription notification to prescriber, New-prescription Alert/ Existing-prescription notification to pharmacist, New-prescription Alert w/ referral option/ Existing-prescription notification to pharmacist
Deep Vein Thrombosis Clinical Trial 2023: New-prescription Alert Highlights & Side Effects. Trial Name: NCT05351749 — N/A
New-prescription Alert 2023 Treatment Timeline for Medical Study. Trial Name: NCT05351749 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment still available for this clinical trial?

"Yes, according to clinicaltrials.gov this healthcare trial is still enrolling participants. It was initially published on August 1st 2022 and the most recent update was made 3 days later. The research team intends to recruit 5000 people from one centre."

Answered by AI

To what extent has participation been seen in this trial?

"Affirmative. Per the information on clinicaltrials.gov, this medical trial is actively recruiting participants. It was first made available to patients on August 1st 2022 and has been updated as recently as August 3rd of that same year. 5,000 individuals will be admitted across a single site location."

Answered by AI
~1739 spots leftby Jul 2024